EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025

Francesca Fortunato, Rosa Prato, Angelo Acquafredda, Angelo Campanozzi, Valeria Delli Carri, Rosa Francavilla, Giuseppina Iannelli, Pio Liberatore, Gianfranco Maffei, Matteo Mariano, Loris Micelli, Marilena Nesta und 5 weitere

Journal of Medical Virology · 2025-11 · 97 (11)

DOI: 10.1002/jmv.70662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 30.10.2025. Verfasst von Francesca Fortunato und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, resulting in millions of cases and hundreds of thousands of deaths worldwide every year. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, has 75%–90% protection against RSV‐related admissions. This study evaluated the effectiveness of nirsevimab in preventing RSV‐hospitalization among infants in southern Italy during 2024–2025 season. Active surveillance was conducted in all hospitals in the Foggia district. Infants born between January 2024 and March 2025 who were hospitalized with lower respiratory tract infections from October 2024 to April 2025 were tested for RSV. Information on immunoprophylaxis was provided by the Regional Immunization Information System. The effectiveness of nirsevimab was estimated using the screening method, a test‐negative case‐control design and a cohort study approach. Of the 4820 eligible infants, 2635 (54.7%) were immunized. Of the 256 infants admitted with lower respiratory tract infections, 82 tested positives for RSV; of these, 13 had received immunoprophylaxis. The effectiveness was estimated to be 84.4% (95% CI: 71.7–91.4%) using the screening method, 72.5% (42.1%–87.0%) using the test‐negative design, and 81.6% (66.4–90.0) using the cohort approach. As in previous study, these findings showed than nirsevimab provide substantial protection against RSV‐related hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationAntiviral AgentsAntibodies, Monoclonal, HumanizedHumansItalyInfantFemaleMaleInfant, NewbornCase-Control StudiesRespiratory Syncytial Virus, HumanCohort Studies

Stichwörter der Autor:innen

NirsevimabRSVRSV hospitalizationsSouth Italyreal‐world effectiveness

Substanzen

Antiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Hygiene Unit, Policlinico Foggia Hospital, Foggia, Italy.
  • Pediatric Unit, Presidio Ospedaliero "Giuseppe Tatarella", Foggia Local Health Unit, Foggia, Italy.
  • Pediatric Unit, Policlinico Foggia Hospital, Foggia, Italy.
  • Microbiology and Virology Unit, Policlinico Foggia Hospital, Foggia, Italy.
  • Pediatric Unit, Ospedale "Teresa Masselli Mascia", Foggia Local Health Unit, Foggia, Italy.

ORCID-Profile: Domenico Martinelli

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Fortunato, F., Prato, R., Acquafredda, A., Campanozzi, A., Carri, V. D., Francavilla, R., Iannelli, G., Liberatore, P., Maffei, G., Mariano, M., Micelli, L., Nesta, M., Pastore, M. R., Calvo, A., Rinaldi, M., Lopalco, P. L., & Martinelli, D. (2025). Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025. Journal of Medical Virology, 97(11). https://doi.org/10.1002/jmv.70662

Vancouver

Fortunato F, Prato R, Acquafredda A, Campanozzi A, Carri VD, Francavilla R, et al. Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025. Journal of Medical Virology. 2025;97(11). doi:10.1002/jmv.70662

BibTeX
@article{Fortunato2025,
  author = {Fortunato, Francesca and Prato, Rosa and Acquafredda, Angelo and Campanozzi, Angelo and Carri, Valeria Delli and Francavilla, Rosa and Iannelli, Giuseppina and Liberatore, Pio and Maffei, Gianfranco and Mariano, Matteo and Micelli, Loris and Nesta, Marilena and Pastore, Maria Rosa and Calvo, Annamaria and Rinaldi, Matteo and Lopalco, Pier Luigi and Martinelli, Domenico},
  title = {Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {11},
  doi = {10.1002/jmv.70662}
}
Kostenlos starten →